Eli Lilly Acquires Disarm and Its SARM1 Inhibitors for Preventing Axonal Degeneration

Eli Lilly Acquires Disarm and Its SARM1 Inhibitors for Preventing Axonal Degeneration

Eli Lilly and Company has acquired Disarm Therapeutics and its emerging  therapies designed to prevent axonal degeneration in neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), multiple sclerosis, and peripheral neuropathy. Disarm’s new class of disease-modifying treatments, called  SARM1 inhibitors, target the central driver of axonal…

When Positivity Becomes a Problem

Last week, we had an early snowfall, even for Michigan’s Keweenaw Peninsula. Snow frosted the tips of trees and blanketed the grass, leaving small bits of green peeking through. I posted a picture on social media and wrote, “It’s beginning to look a lot like Christmas. Gearing up for…

Possible Way Seen of Preventing Inflammation That Precedes ALS Onset

Toxic clumps due to the buildup of the TDP-43 protein can trigger the neuronal inflammation that precedes symptoms of amyotrophic lateral sclerosis (ALS) by activating an inflammatory signaling pathway called cGAS-STING, a study reported. Its findings suggest that targeting this inflammatory signaling may be an effective way of treating ALS.

Adding My Voice to a Valuable Study

I love being in win-win situations. We all do. Especially while world events continue to push the boundaries of our patience. And my latest project offers me many wins: It’s the perfect addition to my current home voice program, and I’m helping to research ALS voice issues. Like 80%…

Diabetes Appears to Lower Risk of ALS, Review Study Reports

People with diabetes mellitus, particularly those with type 2 diabetes, appear to be at a significantly lower risk of amyotrophic lateral sclerosis (ALS) than those without this metabolic disorder, a review study reported. Its findings support previous research suggesting diabetes to be a protective factor against ALS, potentially…

Catalent to Produce BrainStorm’s NurOwn Cell Therapy for ALS

Catalent Biologics has agreed to manufacture NurOwn, the cell-based therapy by BrainStorm Cell Therapeutics being evaluated in a soon-to-conclude pivotal trial as a possible treatment of amyotrophic lateral sclerosis (ALS). With this agreement, Catalent will produce NurOwn under current Good Manufacturing Practices — standards set to ensure that batches…